User login
Key clinical point: Antimicrobial stewardship intervention emerged successful in advocating a shift from broad-spectrum to narrow-spectrum antibiotics for treating moderately severe community-acquired pneumonia (CAP) while averting any safety concerns.
Main finding: Antimicrobial stewardship intervention effectuated a decrease in the adjusted mean broad-spectrum days of therapy per patient from 6.5 days to 4.8 days, with an adjusted relative reduction of 26.6% (95% CI 18.0%-35.3%). The adjusted risk difference of 0.4% (90% CI –2.7% to 2.4%) indicated noninferiority.
Study details: The data come from the investigator-initiated, noninferiority, CAP-PACT trial including 4,084 adult patients receiving antibiotics for moderately severe CAP post admission to a non-ICU hospital ward, of whom 2,235 patients were admitted during the control period and 1,849 during the intervention period.
Disclosures: The authors received no financial support for the study. CH van Werkhoven reported receiving grants, personal fees, and nonfinancial support from a few sources outside the study, in addition to obtaining a patent for the prediction of clinical manifestations of gut microbiota.
Source: Schweitzer VA et al. Lancet Infect Dis. 2021(Oct 7). Doi: 10.1016/S1473-3099(21)00255-3.
Key clinical point: Antimicrobial stewardship intervention emerged successful in advocating a shift from broad-spectrum to narrow-spectrum antibiotics for treating moderately severe community-acquired pneumonia (CAP) while averting any safety concerns.
Main finding: Antimicrobial stewardship intervention effectuated a decrease in the adjusted mean broad-spectrum days of therapy per patient from 6.5 days to 4.8 days, with an adjusted relative reduction of 26.6% (95% CI 18.0%-35.3%). The adjusted risk difference of 0.4% (90% CI –2.7% to 2.4%) indicated noninferiority.
Study details: The data come from the investigator-initiated, noninferiority, CAP-PACT trial including 4,084 adult patients receiving antibiotics for moderately severe CAP post admission to a non-ICU hospital ward, of whom 2,235 patients were admitted during the control period and 1,849 during the intervention period.
Disclosures: The authors received no financial support for the study. CH van Werkhoven reported receiving grants, personal fees, and nonfinancial support from a few sources outside the study, in addition to obtaining a patent for the prediction of clinical manifestations of gut microbiota.
Source: Schweitzer VA et al. Lancet Infect Dis. 2021(Oct 7). Doi: 10.1016/S1473-3099(21)00255-3.
Key clinical point: Antimicrobial stewardship intervention emerged successful in advocating a shift from broad-spectrum to narrow-spectrum antibiotics for treating moderately severe community-acquired pneumonia (CAP) while averting any safety concerns.
Main finding: Antimicrobial stewardship intervention effectuated a decrease in the adjusted mean broad-spectrum days of therapy per patient from 6.5 days to 4.8 days, with an adjusted relative reduction of 26.6% (95% CI 18.0%-35.3%). The adjusted risk difference of 0.4% (90% CI –2.7% to 2.4%) indicated noninferiority.
Study details: The data come from the investigator-initiated, noninferiority, CAP-PACT trial including 4,084 adult patients receiving antibiotics for moderately severe CAP post admission to a non-ICU hospital ward, of whom 2,235 patients were admitted during the control period and 1,849 during the intervention period.
Disclosures: The authors received no financial support for the study. CH van Werkhoven reported receiving grants, personal fees, and nonfinancial support from a few sources outside the study, in addition to obtaining a patent for the prediction of clinical manifestations of gut microbiota.
Source: Schweitzer VA et al. Lancet Infect Dis. 2021(Oct 7). Doi: 10.1016/S1473-3099(21)00255-3.